We performed a quantitative study of serum hepatitis B virus (HBV) markers, including new parameters such as pre-SI antigen (Ag), pre-S2 Ag, and anti-HBx, in 88 chronic hepatitis B surface antigen (HBsAg) carriers. New IMx assays for HBsAg and immunoglobulin M (IgM) anti-HBc detection were also used. The population studied was composed of 65 chronic hepatitis cases (40 positive for hepatitis B antigen [HBeAg] and 25 positive for anti-HBe) and 23 anti-HBe-positive, asymptomatic HBsAg carriers. Serum HBsAg levels detected by IMx were higher in HBeAg-positive than in anti-HBe-positive HBsAg carriers (all patient subgroups included) and correlated with the serum HBV DNA level (P = 0.0001). Both pre-Sl and pre-S2 Ags were detected by enzyme immunoassays in almost all HBsAg carriers. Both pre-SI and pre-S2 Ag titers correlated positively with the serum HBsAg concentration (P = 0.0001), but only the pre-SI Ag titer correlated with the level of serum HBV DNA (P = 0.02). The detection of low levels of IgM anti-hepatitis B core (anti-HBc) antibodies by IMx was associated with the presence of liver disease (P = 0.05) but not with the level of viral replication. The prevalence of anti-HBx antibodies detected by the enzyme immunoassay was slightly, although not significantly, higher in patients with high levels of HBV DNA (>100 pg/mI) than in patients without detectable HBV DNA (P = 0.16). In anti-HBe-positive chronic HBsAg carriers, the quantitative detection of serum HBV DNA, pre-S Ag titers, and IgM anti-HBc allowed us to predict which patients suffered from chronic liver disease and/or supported viral replication (P < 0.05). In a follow-up study of eight patients undergoing antiviral therapy, the clearance of both pre-Sl Ag and HBV DNA was associated with a subsequent clearance of HBV. Therefore, the quantitative determination of HBV DNA, pre-S Ags, and IgM anti-HBc may prove useful for the decision to use and the monitoring of antiviral therapy, especially in anti-HBe-positive HBsAg carriers.
Hepatitis B virus (HBV) infection causes a wide spectrum of clinical conditions. Schematically, patients with chronic HBV infection can be divided into two groups: (i) the healthy asymptomatic, chronic hepatitis B surface antigen (HBsAg) carriers with low-grade HBV replication and normal liver function tests and (ii) the chronic hepatitis (CH) B patients with active viral replication and progressive liver disease that may lead to cirrhosis and hepatocellular carcinoma (these patients may or may not be symptomatic) (1, 17, 20) . The natural history of chronic HBV infection is characterized by a slow transition from a phase of active HBV replication to a phase of low viral replication (1, 17, 20) . The early replicative phase is associated with the production of hepatitis B envelope antigen (HBeAg) in serum and hepatitis B core antigen (HBcAg) in liver and the presence of CH (17, 33) . The later, low-replication phase is accompanied by seroconversion from HBeAg to anti-HBe, which is usually followed by the remission of liver disease (16, 17, 33) . The detection of serum HBV DNA has been shown as the most reliable marker of HBV replication, while the HBe versus the anti-HBe status has not always permitted the differentiation of the two phases (the active-replication phase versus the low-replication phase) of chronic HBV infection (5, 14, 29) . Indeed, in a significant proportion of cases, the detection of significant levels of serum HBV DNA indicates active HBV replication in anti-HBe-positive chronic HBV infection (3, 14) . These related to mutations in the precore region of the HBV genome leading to a stop codon (TAG) that prevents the synthesis of HBe Ag (7, 32) . In some of these cases, the course of CH may be more severe and/or rapidly progressive than with wild-type virus infection (3, 10) . The assessment of HBV replication in these anti-HBe-positive CH infections may be difficult since circulating HBV DNA is often transient and fluctuating at low levels (3, 10) . The polymerase chain reaction (PCR) is the most sensitive method for the detection of HBV DNA and may be useful especially in anti-HBe-positive CH for the diagnosis of low-grade HBV replication (1, 12, 20) . PCR amplification is also necessary for the detection of the mutations in the precore region of the HBV genome (25) . However, the PCR is not yet widely available for clinical purposes.
Another postulated serological marker for the presence of active HBV replication and accompanying active liver disease is immunoglobulin M anti-hepatitis B core (IgM antiHBc) antibodies, but its clinical relevance depends on the sensitivity of the assay and remains undetermined in chronic HBV infection (2, 23) . The clinical significance of pre-Sl and pre-S2 protein detection in serum is still a matter of controversy: several studies concerning pre-S detection in relation to markers of HBV replication have led to opposite results (6, 12, 13, 18, 19, 28, 30, 35) . Conflicting findings regarding the correlation of anti-HBx antibodies with the intensity of HBV replication or the clinical status of HBV-infected patients have been reported (11, 24, 31, 34 (26) . Therefore, in the present study, pre-S Ag testing was performed with diluted serum specimens and at further 10-fold dilutions to determine the clinical relevance of this quantitative assay. Serum samples were diluted 1:10 in 5% bovine serum albumin and then incubated overnight at room temperature for 18 h with Auszyme II beads (Abbott). After being washed with water, the beads were incubated with 200 ,ul of peroxidase-conjugated monoclonal antibodies for 2 h at 40°C. The beads were washed with water and incubated with 300 ,ul of a solution containing O-phenylenediamine and H202. After 30 min of incubation at room temperature, the reaction was stopped by adding 1 ml of 1 N H2SO4, and the resulting optical density at 492 nm was determined by using a photoenzyme-linked immunosorbent assay colorimeter (Abbott).
For pre-Sl Ag detection, peroxidase-conjugated monoclonal antibodies 116-80 and 116-86, which recognize epitopes of the pre-Sl region, were used as the detection system. The fine specificity of these monoclonal antibodies is described in detail elsewhere (27) . The cutoff value was calculated as the mean optical density of negative controls plus 0.05. For a quantitative analysis of pre-Sl Ag, the test sera positive for pre-SI Ag were diluted 10-fold with 5% bovine serum albumin. The pre-Sl Ag titer was expressed by the highest positive 10-fold dilution of the test serum.
For pre-S2 Ag detection, peroxidase-conjugated monoclonal antibodies 50-80, 25-19, and 116-34, which are described elsewhere (27) , were used as the detection system. The cutoff value was calculated as described for the pre-Sl Ag assay. The pre-S2 Ag titer was expressed by the highest positive 10-fold dilution of the test serum.
Detection of IgM anti-HBc by IMx core M. The presence of IgM anti-HBc antibodies was tested in serum by IMx core M (Abbott) as previously described (9) . Briefly, each specimen was diluted by the IMx instrument. Microparticles coated with anti-human IgM antibody (p, chain) were used to capture IgM in the diluted specimen. A recombinant-derived HBcAg is added, and if IgM anti-HBc is present in the sample, the HBcAg binds to the microparticle-antibody complex. Human anti-HBc-alkaline phosphatase conjugate is dispensed and binds to the microparticle antibody-antigen complex. The microparticle complex captured on the matrix is washed to remove unbound material, and the substrate MUP is added to the matrix. The rate of production of fluorescent product is proportional to the amount of IgM anti-HBc captured and is normalized to the Mode 1 calibrator rate to give an index value. Specimens giving index values between 0.800 and 1.200 were considered "gray zone" reactive, and specimens giving index values greater than 1.200 were considered reactive in the assay. The sensitivity, reproducibility, and specificity of the assay were previously determined (9) .
Detection of anti-HBx antibodies by ELISA. Serum samples from 84 of the 88 chronic HBsAg carriers were available for anti-HBx testing. Detection of anti-HBx antibodies by an enzyme-linked immunosorbent assay (ELISA) was carried out as described elsewhere (34) . Briefly, a purified recombinant HBx preparation was coated on Microwell III assay plates at a concentration of 1 to 1.5 mg/ml in phosphatebuffered saline (PBS), pH 7.2, by incubation overnight at 4°C. After washing with PBS-5% Tween 20, the plates were overcoated with PBS-5% casein for 90 min at 37°C. The microwells were then reacted with human sera at both 1:100 and 1:200 dilutions in PBS-casein for 90 min at 37°C. After washing with PBS-Tween 20, goat anti-human immunoglobulin coupled to alkaline phosphatase in PBS-casein was added to the microwells and incubated at 37°C for 90 min. The plates were washed with PBS-Tween 20, and phosphatase substrate in diethanolamine (1 mol/liter, pH 9.8) was added. After 1 h at 37°C, the results were read spectrophotometrically. Sera with absorbance values three times higher than that of normal serum were considered positive for anti-HBx antibodies. To quantify the results, an index value was calculated as the serum sample optical density/cutoff value.
Solution hybridization assay for HBV DNA. The solution hybridization assay for HBV DNA in serum was performed as previously described (22) , and results were quantified according to the procedures and the formulas described in the Abbott commercial test kit (Genostic). One-hundred microliters of serum was denatured and then hybridized in solution for 16 to 18 h at 65°C. The hybridization mixture was then applied to a gel matrix to separate hybrids from free probe. 125I-DNA probe hybridized to HBV DNA sequences eluted from the matrix, while free probe remained on the gel column. After the radioactivity was determined with a y counter for 10 min, HBV DNA-positive samples were quantitated by using the positive control standard and results were expressed in picograms of HBV DNA per milliliter. The sensitivity of the assay was 0.15 pg of HBV DNA.
PCR assay for HBV DNA. The PCR assay for serum HBV DNA was performed as described previously in detail (8) for a separate additional group of 31 anti-HBe-positive chronic HBsAg carriers (11 CH cases and 20 ASC cases); pre-SI Ag testing was also performed in the same undiluted serum specimens for comparison.
(i) Preparation of DNA samples from serum. Five-hundred microliters of serum was incubated at 55°C for 1 h in Tris-HCl (pH 8)-i mM EDTA-100 mM NaCl-proteinase K (500 ,ug/ml). After three phenol-chloroform extractions, the DNA was precipitated overnight with ethanol in the presence of 3 M sodium acetate, pH 5.2, at -20°C. The precipitate was redissolved in 100 ,ul of H20.
(ii) PCR assay. Oligonucleotides were synthesized by using a DNA synthesizer apparatus (Applied Biosystems). Oligonucleotide primers specific for the most-conserved C and S gene sequences of HBV genome were selected according to the sequence kindly provided by J. Sninsky from the Cetus Corporation, as described in detail (8) . Primers MDO3 (position 736 to 759) and MDO6 (position 637 to 651) and the probe MDO9 are located in the S gene sequence. Primers MD25 (position 1959 to 1980) and MD27 (position 1856 to 1881) and the probe MD28 are located in the C gene region.
DNA extracted from 500 RI of serum was amplified as described previously (8) . Target sequences were amplified in a 50-,ul reaction mixture containing 1 ,ug of the serum DNA sample, 1 U of Taq polymerase (Perkin-Elmer Cetus), 187 ,uM each deoxynucleoside triphosphate, 50 pmol of each primer, 40 mM KCI, 50 mM Tris-HCl, and 6 mM MgCl2.
Mixtures were overlaid with 100 pA of mineral oil to prevent evaporation. The reaction was performed for 30 cycles in a programmable DNA thermal cycler (Perkin-Elmer Cetus). During each cycle, samples were heated to 95°C for 25 s, cooled to 55°C for 25 s, and then incubated for 1 min at 72°C.
To eliminate sources of contamination, reagents were aliquoted and stored in new disposable containers. All experiments were performed in parallel with serum samples from positive and negative controls and with the reaction mixture without DNA. Each sample was tested in at least two different series for each set of primers.
(iii) Analysis of PCR amplification products. For each sample, a 10-pA aliquot of the amplified DNA reaction mixture was analyzed by ethidium bromide coloration after gel electrophoresis and Southern blot hybridization (SBH) analysis after electrophoresis as described previously (8) .
Probes designated MDO9 for the S gene and MD28 for the C gene were labeled by terminal transferase with a 3-endlabeling kit (Boehringer GmbH, Mannheim, Germany) by using [32P]dCTP (3, 000 Ci/mmol; Amersham) to a specific activity of 106 cpm/ml in hybridization medium. The hybridization solution for the nucleotide probes contained 3 x SSPE (1x SSPE is 0.18 M NaCl, 10 mM sodium phosphate [pH 7.4], and 1 mM EDTA), 5x Denhardt's solution, 30% (vol/vol) formamide, and 0.5% sodium dodecyl sulfate (SDS). The membrane (Hybond N; Amersham) was hybridized with standard labeled specific probe at 42°C overnight. Excess probe was removed by two washes with 2x SSPE-0.1% SDS and an additional wash with 0.2x SSPE-0.1% SDS for 30 min at 42°C. The membrane was exposed for 1 h and overnight at -70°C with two intensifying screens to X-ray film (Hyperfilm; Amersham) for autoradiography. The sensitivity of the PCR-SBH assay was 10-i pg of HBV DNA (8) .
Statistical analysis. Differences in the mean value of each group were evaluated by an analysis of variance or Kruskall Wallis test for noncontinuous variables. The correlations between the variables were calculated by using simple regression analysis. The prevalences of the different viral markers were compared by using the chi-square test. (Table 1) . A quantitative determination of HBsAg showed that the mean serum HBsAg concentration was higher in HBeAg-positive CH than in anti-HBe-positive chronic HBsAg carriers whether they were ASC or patients with chronic liver disease (P < 0.05) ( Table 2) .
(ii) Pre-S Ag detection in serum. By using specimens diluted 1:10, the prevalence of pre-SI Ag in anti-HBepositive ASC sera (61%) was significantly lower than that in VOL. 30, 1992 on November 6, 2017 by guest http://jcm.asm.org/ Downloaded from anti-HBe-positive CH cases (100%) and in HBeAg-positive CH cases (100%) (P < 0.05) ( Table 1) . Pre-Sl titers were higher in both CH patient groups (positive for HBeAg or anti-HBe) than in anti-HBe-positive ASC (P < 0.05) ( Table  2) .
Pre-S2 Ag was detected in the serum samples of all but one chronic HBsAg carriers (Table 1) . Pre-S2 titers were higher in both CH groups (positive for HBeAg or anti-HBe) than in anti-HBe-positive ASC (P <0. 05) ( (Table 2) .
(iv) Detection of anti-HBx antibodies by ELISA. Antihepatitis B x gene product (anti-HBx) antibodies were found in the serum samples of 45% of anti-HBe-positive ASC cases, 29% of anti-HBe-positive CH cases, and 47% of HBeAg-positive CH cases (P > 0.05) ( Table 1 ). The mean anti-HBx index value was higher in HBeAg-positive CH cases than in anti-HBe-positive CH cases (P < 0.05) ( Table  2) .
(v) Detection of serum HBV DNA by solution hybridization assay. HBV DNA was detected in the serum samples of 9% of anti-HBe-positive ASC cases, 44% of anti-HBe-positive CH cases, and 80% of HBe-positive CH cases (P < 0.05) ( Table 1 ). The mean serum HBV DNA level was higher in the HBeAg-positive CH group than in both groups of antiHBe-positive chronic HBsAg carriers with or without liver disease (P < 0.05) ( Table 2) .
Determination of HBV markers in relation to the level of HBV replication. We analyzed the correlation between the different HBV markers and the levels of serum HBV DNA in 88 chronic HBsAg carriers. As shown in Fig. 1 , the serum HBsAg concentration correlated positively with the serum HBV DNA level (r = 0.55; P = 0.0001). Pre-Sl Ag titers correlated positively with the serum HBV DNA level (r = 0.24; P = 0.02), while pre-S2 titers did not (r = 0.01; P = 0.86) (Fig. 2) . It was noteworthy that both pre-Sl Ag and pre-S2 Ag titers correlated positively with the HBsAg concentration in serum (r = 0.44; P = 0.0001). The index value of IgM anti-HBc did not statistically correlate with the serum HBV DNA level (P = 0.44). The index value of anti-HBx antibodies did not correlate with the serum HBV DNA level (r = 0.03; P = 0.76). However, the prevalence of anti-HBx antibodies was higher (53%) in patients with high viral replication (serum HBV DNA, >100 pg/ml) than in patients without detectable serum HBV DNA (33%), but this difference did not reach statistical significance (P = 0.16).
Detection of HBV markers in HBeAg-positive CH patients during antiviral therapy. Thirty-one serial serum samples were available from 8 HBsAg-positive patients undergoing antiviral therapy (Interferon and/or ara-AMP).
In two cases, interferon therapy induced HBV DNA clearance with a persistence of HBsAg. In these two cases, the HBV DNA disappearance from serum samples was associated with a decrease in the HBsAg concentration, in the pre-S2 Ag and pre-Sl Ag titers, and, in one case, in the IgM anti-HBc index from the gray zone to a negative value. Anti-HBx antibodies were negative in one case and remained positive during the follow-up in the other case.
In three cases, anti-HBe seroconversion was observed. Two patients received interferon, and one received interferon in combination with ara-AMP. The serum HBsAg concentration decreased at the time of anti-HBe seroconversion in all three cases. The pre-Sl Ag titer diminished in two cases, while the pre-S2 Ag titer diminished in only one case at the time of anti-HBe seroconversion. The IgM anti-HBc index value, although initially negative in all three cases, decreased after anti-HBe seroconversion. Anti-HBx antibodies were positive in two cases, and the anti-HBx index value decreased in these two cases after anti-HBe seroconversion but remained positive.
Three patients cleared HBsAg from serum samples. Two patients received interferon, and one received interferon in combination with ara-AMP. In these cases, both HBV DNA and pre-Sl Ag first became negative, followed by the con- not be demonstrated by serum HBV DNA detection. Since both pre-SI Ag and pre-S2 Ag titers were higher in anti-HBepositive CH cases than in ASC cases (Table 2) , we looked for a cutoff titer which might be useful to discriminate between CH and ASC cases. We found that 68% of antiHBe-positive CH cases had pre-Sl Ag titers higher than 1:100 versus 13% of ASC cases (P < 0.001). Furthermore, 84% of anti-HBe-positive CH cases had pre-S2 Ag titers higher than 1:1,000 versus 30% of ASC cases (P < 0.001).
The HBsAg concentration was higher in anti-HBe-positive CH cases than in ASC cases, but the difference was not statistically significant (Table 2 ). Both the prevalence of IgM anti-HBc antibodies and the mean index value were slightly higher in anti-HBe-positive CH cases than in ASC cases, but the differences did not reach statistical significance (Tables 1  and 2 ). However, when samples gray zone reactive for IgM anti-HBc (index value, >0.800) were taken into account, the prevalence of IgM anti-HBc antibodies became significantly (22) . In our population of chronic HBsAg carriers, almost all (80%) HBeAg-positive CH cases had serum HBV DNA, while 44% of anti-HBe CH cases and less than 10% of anti-HBe positive ASC were positive for serum HBV DNA, in agreement with other reports using the spot hybridization method (3, 5, 10, 14, 29) . The serum HBV DNA level was also higher in HBeAg-positive CH cases than in anti-HBe CH cases, as previously described (3, 10 Both pre-Sl and pre-S2 antigens were determined quantitatively by an enzyme immunoassay. In the pre-S assay system, a collection of labeled monoclonal antibodies directed against different epitopes of the pre-S region (27) was used in order to obtain a very sensitive assay that would not be significantly influenced by HBV subtype, pre-S variant, or epitope masking by endogenous anti-pre-S antibodies. Both pre-Sl and pre-S2 antigens were detected in almost all of the undiluted serum samples of chronic HBsAg carriers, as previously reported by other groups utilizing sensitive enzyme immunoassays or radioimmunoassays for pre-S Ag detection (6, 18, 19, 35) . By using serum specimens diluted 1:10, the prevalence of pre-Sl Ag in anti-HBe-positive ASC (61%) was significantly lower than in HBeAg-or anti-HBepositive CH cases (100%). These changes underscore the point that pre-Sl Ag and pre-S2 Ag can be detected in virtually all chronic HBsAg carriers but that a 1:10 dilution allows a clinically relevant statement to be made. Pre-S Ag titration showed that both pre-Sl and pre-S2 titers were higher in CH cases (whether they were HBeAg positive or anti-HBe positive) than in anti-HBe-positive ASC, suggesting that these ASC may support a low level of viral replication (1, 8, 12, 20, 28, 35) . The quantitative determination of pre-S antigens in relation to the level of HBV replication showed that pre-Sl Ag titers correlated positively with the HBV DNA level while pre-S2 Ag titers did not. These data are in agreement with the preferential localization of pre-Sl epitopes on the envelope of Dane particles as detected with monoclonal anti-pre-S antibodies (27) . Both pre-Sl and pre-S2 Ag titers correlated positively with the HBsAg level as shown by others (18, 35) . Altogether, these findings suggest that the quantitative determination of pre-Sl Ag may prove useful as a marker for the level of HBV replication (13, 19, 28, 30) and that pre-S2 Ag detection is more closely related to that of HBsAg than to the level of viral replication (28) .
Anti-HBx antibody detection was performed by using a sensitive enzyme immunoassay (34) . The anti-HBx prevalence was approximately 40% in our population of chronic HBsAg carriers. The prevalence of anti-HBx was not associated with the severity of liver disease (31, 34) . The high prevalence of anti-HBx in anti-HBe ASC (45%) compared with the results from our first study (16%) may be explained by the lower number of healthy blood donors devoid of HBV replication in our present study (34) . There was a trend towards a correlation between the presence of anti-HBx and a high viral DNA level in serum, suggesting that anti-HBx VOL. 30, 1992 on November 6, 2017 by guest http://jcm.asm.org/ Downloaded from may represent a marker of HBV replication (24, 34) . We are currently studying the clinical significance of the differential recognition of the N-terminal, C-terminal, and interior portions of HBx by sera from HBV-infected patients in relation to their viral and clinical statuses (21 
